AstraZeneca
Public AZN · United Kingdom
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
22 approved
21 in Phase 3
Drugs
107
in active trials · 243 in all
Trials
372 active
944 since 2021
Drugs107
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
PD-L1 antibody |
Approved | 30 Nov 2026soonPhase 2 trial completes | |||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Hepatocellular Carcinoma and 79 more | ||||
| Open drug page | |||||
CTLA-4 antibody |
Approved | 30 Nov 2026soonPhase 2 trial completes | |||
| How it works | A cancer drug that hits three targets | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Unresectable Pleural or Peritoneal Malignant Mesothelioma and 15 more | ||||
| Open drug page | |||||
— |
Approved | 10 Dec 2026soonPhase 2 trial completes | |||
| Next date | 10 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Primary Hyperaldosteronism, Chronic Kidney Disease and Hypertension and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 23 Dec 2026Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 23 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) and 4 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 6 Jan 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 6 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Lupus Nephritis and 6 more | ||||
| Open drug page | |||||
TROP2-targeted antibody-drug conjugate |
Daiichi Sankyo |
Approved | 11 Jan 2027Phase 3 trial completes | ||
| Next date | 11 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Breast Cancer and 28 more | ||||
| Open drug page | |||||
EGFR inhibitor (third generation) |
Approved | 11 Jan 2027Phase 3 trial completes | |||
| Next date | 11 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung and 15 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 13 Jan 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 13 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Severe Asthma, Chronic Rhinosinusitis With Nasal Polyps and 3 more | ||||
| Open drug page | |||||
MET inhibitor |
HUTCHMED |
Approved in China | 18 Jan 2027Phase 2 trial completes | ||
| Next date | 18 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small Cell Lung Cancer and 11 more | ||||
| Open drug page | |||||
— |
Approved | 3 Feb 2027Phase 4 trial completes | |||
| Next date | 3 Feb 2027 · Phase 4 trial completes | ||||
| Also tested for | Asthma | ||||
| Open drug page | |||||
Monoclonal antibody |
Daiichi Sankyo |
Approved | 10 Feb 2027Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 10 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Breast Cancer, Non-Small Cell Lung Cancer and 43 more | ||||
| Open drug page | |||||
Acalabrutinibnot checked |
Kinase inhibitor |
Approved | 15 Feb 2027Phase 3 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 15 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL) and 20 more | ||||
| Open drug page | |||||
Sodium-Glucose cotransporter 2 inhibitor |
Approved | 18 Feb 2027Phase 3 trial completes | |||
| How it works | Makes the kidneys flush extra sugar and salt into the urine | ||||
| Next date | 18 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Kidney Disease With High Proteinuria, Type 2 diabetes and 4 more | ||||
| Open drug page | |||||
Poly(ADP-Ribose) polymerase inhibitor |
Approved | 6 Apr 2027Phase 3 trial completes | |||
| How it works | Blocks PARP | ||||
| Next date | 6 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Ovarian Cancer, Breast Cancer and 23 more | ||||
| Open drug page | |||||
— |
Approved | 20 Apr 2027Phase 3 trial completes | |||
| Next date | 20 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | ER-Positive HER2-Negative Breast Cancer, ER+ HER2- Advanced Breast Cancer and 17 more | ||||
| Open drug page | |||||
— |
Approved | 31 May 2027Phase 4 trial completes | |||
| Next date | 31 May 2027 · Phase 4 trial completes | ||||
| Also tested for | COPD (Chronic Obstructive Pulmonary Disease), Moderate to Severe COPD and 2 more | ||||
| Open drug page | |||||
— |
Approved | 1 Nov 2027Phase 3 trial completes | |||
| Next date | 1 Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Triple Negative Breast Neoplasms, Locally Advanced (Inoperable) or Metastatic Breast Cancer and 6 more | ||||
| Open drug page | |||||
Estrogen receptor antagonist |
Approved | 1 Nov 2027Phase 3 trial completes | |||
| How it works | Blocks oestrogen from acting on cells | ||||
| Next date | 1 Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Breast Cancer, Locally Advanced (Inoperable) or Metastatic Breast Cancer and 4 more | ||||
| Open drug page | |||||
MEK inhibitor |
Approved | 30 Nov 2027Phase 1/2 trial completes | |||
| Next date | 30 Nov 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Neurofibromatosis 1, Neurofibromatosis Type 1 and 8 more | ||||
| Open drug page | |||||
Transthyretin-directed RNA Interaction; antisense oligonucleotide |
Ionis Pharmaceuticals |
Approved | 6 Feb 2029Phase 2 trial completes | ||
| How it works | A short strand of genetic material that blocks one gene's message | ||||
| Next date | 6 Feb 2029 · Phase 2 trial completes | ||||
| Also tested for | Hereditary Transthyretin-Mediated Amyloid Polyneuropathy, Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings301
Since Jan 2024 · All on SEC.gov- 16 NovFiled a report · SEC 6-K
- 16 NovFiled a report · SEC 6-K
- 16 NovFiled a report · SEC 6-K
- 16 NovFiled a report · SEC 6-K
- 2 NovFiled a report · SEC 6-K
- 2 NovFiled a report · SEC 6-K
- 30 OctFiled a report · SEC 6-K
- 27 OctFiled a report · SEC 6-K
- 22 OctFiled a report · SEC 6-K
- 5 OctFiled a report · SEC 6-K
- 2 OctFiled a report · SEC 6-K
- 1 OctFiled a report · SEC 6-K
- 1 OctFiled a report · SEC 6-K
- 29 SepFiled a report · SEC 6-K
- 23 SepFiled a report · SEC 6-K
- 21 SepFiled a report · SEC 6-K
- 21 SepFiled a report · SEC 6-K
- 18 SepFiled a report · SEC 6-K
- 15 SepFiled a report · SEC 6-K
- 15 SepFiled a report · SEC 6-K
- 14 SepFiled a report · SEC 6-K
- 8 SepFiled a report · SEC 6-K
- 8 SepFiled a report · SEC 6-K
- 1 SepFiled a report · SEC 6-K
- 1 SepFiled a report · SEC 6-K
- 1 SepFiled a report · SEC 6-K
- 1 SepFiled a report · SEC 6-K
- 1 SepFiled a report · SEC 6-K
- 1 SepFiled a report · SEC 6-K
- 1 SepFiled a report · SEC 6-K
- 27 AugFiled a report · SEC 6-K
- 25 AugFiled a report · SEC 6-K
- 19 AugFiled a report · SEC 6-K
- 17 AugFiled a report · SEC 6-K
- 17 AugFiled a report · SEC 6-K
- 17 AugFiled a report · SEC 6-K
- 3 AugFiled a report · SEC 6-K
- 3 AugFiled a report · SEC 6-K
- 31 JulFiled a report · SEC 6-K
- 27 JulFiled a report · SEC 6-K
- 27 JulFiled a report · SEC 6-K
- 27 JulFiled a report · SEC 6-K
- 23 JulFiled a report · SEC 6-K
- 14 JulFiled a report · SEC 6-K
- 9 JulFiled a report · SEC 6-K
- 1 JulFiled a report · SEC 6-K
- 1 JulFiled a report · SEC 6-K
- 29 JunFiled a report · SEC 6-K
- 29 JunFiled a report · SEC 6-K
- 15 JunFiled a report · SEC 6-K
- 1 JunFiled a report · SEC 6-K
- 1 JunFiled a report · SEC 6-K
- 29 MayFiled a report · SEC 6-K
- 27 MayFiled a report · SEC 6-K
- 26 MayFiled a report · SEC 6-K
- 26 MayFiled a report · SEC 6-K
- 26 MayFiled a report · SEC 6-K
- 18 MayFiled a report · SEC 6-K
- 18 MayFiled a report · SEC 6-K
- 18 MayFiled a report · SEC 6-K
- 14 MayFiled a report · SEC 6-K
- 1 MayFiled a report · SEC 6-K
- 1 MayFiled a report · SEC 6-K
- 1 MayFiled a report · SEC 6-K
- 29 AprFiled a report · SEC 6-K
- 28 AprFiled a report · SEC 6-K
- 27 AprFiled a report · SEC 6-K
- 23 AprFiled a report · SEC 6-K
- 21 AprFiled a report · SEC 6-K
- 20 AprFiled a report · SEC 6-K
- 9 AprFiled a report · SEC 6-K
- 2 AprFiled a report · SEC 6-K
- 1 AprFiled a report · SEC 6-K
- 31 MarFiled a report · SEC 6-K
- 27 MarFiled a report · SEC 6-K
- 20 MarFiled a report · SEC 6-K
- 16 MarFiled a report · SEC 6-K
- 10 MarFiled a report · SEC 6-K
- 10 MarFiled a report · SEC 6-K
- 6 MarFiled a report · SEC 6-K
- 6 MarFiled a report · SEC 6-K
- 6 MarFiled a report · SEC 6-K
- 2 MarFiled a report · SEC 6-K
- 2 MarFiled a report · SEC 6-K
- 27 FebOffered new securities · 1 prospectus (424B2)
- 26 FebFiled a report · SEC 6-K
- 25 FebOffered new securities · 1 prospectus (424B2)
- 25 FebFiled a report · SEC 6-K
- 24 FebFiled a report · SEC 6-K
- 24 FebFiled a report · SEC 6-K
- 24 FebFiled a report · SEC 6-K
- 20 FebFiled a report · SEC 6-K
- 10 FebFiled a report · SEC 6-K
- 3 FebFiled a report · SEC 6-K
- 2 FebFiled a report · SEC 6-K
- 2 FebFiled a report · SEC 6-K
- 2 FebFiled a report · SEC 6-K
- 30 JanFiled a report · SEC 6-K
- 29 JanFiled a report · SEC 6-K
- 20 JanFiled a report · SEC 6-K
- 8 JanFiled a report · SEC 6-K
- 2 JanFiled a report · SEC 6-K
- 22 Dec 2025Filed a report · SEC 6-K
- 22 Dec 2025Filed a report · SEC 6-K
- 22 Dec 2025Filed a report · SEC 6-K
- 19 Dec 2025Filed a report · SEC 6-K
- 16 Dec 2025Filed a report · SEC 6-K
- 16 Dec 2025Filed a report · SEC 6-K
- 4 Dec 2025Filed a report · SEC 6-K
- 1 Dec 2025Filed a report · SEC 6-K
- 1 Dec 2025Filed a report · SEC 6-K
- 26 Nov 2025Filed a report · SEC 6-K
- 24 Nov 2025Filed a report · SEC 6-K
- 20 Nov 2025Filed a report · SEC 6-K
- 17 Nov 2025Filed a report · SEC 6-K
- 14 Nov 2025Filed a report · SEC 6-K
- 10 Nov 2025Filed a report · SEC 6-K
- 6 Nov 2025Filed a report · SEC 6-K
- 3 Nov 2025Filed a report · SEC 6-K
- 3 Nov 2025Filed a report · SEC 6-K
- 3 Nov 2025Filed a report · SEC 6-K
- 28 Oct 2025Filed a report · SEC 6-K
- 28 Oct 2025Filed a report · SEC 6-K
- 22 Oct 2025Filed a report · SEC 6-K
- 20 Oct 2025Filed a report · SEC 6-K
- 20 Oct 2025Filed a report · SEC 6-K
- 14 Oct 2025Filed a report · SEC 6-K
- 7 Oct 2025Filed a report · SEC 6-K
- 6 Oct 2025Filed a report · SEC 6-K
- 1 Oct 2025Filed a report · SEC 6-K
- 29 Sep 2025Filed a report · SEC 6-K
- 29 Sep 2025Filed a report · SEC 6-K
- 29 Sep 2025Filed a report · SEC 6-K
- 25 Sep 2025Filed a report · SEC 6-K
- 22 Sep 2025Filed a report · SEC 6-K
- 22 Sep 2025Filed a report · SEC 6-K
- 17 Sep 2025Filed a report · SEC 6-K
- 17 Sep 2025Filed a report · SEC 6-K
- 2 Sep 2025Filed a report · SEC 6-K
- 28 Aug 2025Filed a report · SEC 6-K
- 26 Aug 2025Filed a report · SEC 6-K
- 21 Aug 2025Filed a report · SEC 6-K
- 18 Aug 2025Filed a report · SEC 6-K
- 15 Aug 2025Filed a report · SEC 6-K
- 12 Aug 2025Filed a report · SEC 6-K
- 1 Aug 2025Filed a report · SEC 6-K
- 29 Jul 2025Filed a report · SEC 6-K
- 24 Jul 2025Filed a report · SEC 6-K
- 22 Jul 2025Filed a report · SEC 6-K
- 16 Jul 2025Filed a report · SEC 6-K
- 14 Jul 2025Filed a report · SEC 6-K
- 7 Jul 2025Filed a report · SEC 6-K
- 1 Jul 2025Filed a report · SEC 6-K
- 24 Jun 2025Filed a report · SEC 6-K
- 13 Jun 2025Filed a report · SEC 6-K
- 12 Jun 2025Filed a report · SEC 6-K
- 6 Jun 2025Filed a report · SEC 6-K
- 2 Jun 2025Filed a report · SEC 6-K
- 2 Jun 2025Filed a report · SEC 6-K
- 27 May 2025Filed a report · SEC 6-K
- 23 May 2025Filed a report · SEC 6-K
- 21 May 2025Filed a report · SEC 6-K
- 20 May 2025Filed a report · SEC 6-K
- 9 May 2025Filed a report · SEC 6-K
- 7 May 2025Filed a report · SEC 6-K
- 6 May 2025Filed a report · SEC 6-K
- 2 May 2025Filed a report · SEC 6-K
- 1 May 2025Filed a report · SEC 6-K
- 1 May 2025Filed a report · SEC 6-K
- 29 Apr 2025Filed a report · SEC 6-K
- 29 Apr 2025Filed a report · SEC 6-K
- 29 Apr 2025Filed a report · SEC 6-K
- 22 Apr 2025Filed a report · SEC 6-K
- 11 Apr 2025Filed a report · SEC 6-K
- 4 Apr 2025Filed a report · SEC 6-K
- 4 Apr 2025Filed a report · SEC 6-K
- 1 Apr 2025Filed a report · SEC 6-K
- 31 Mar 2025Filed a report · SEC 6-K
- 31 Mar 2025Filed a report · SEC 6-K
- 21 Mar 2025Filed a report · SEC 6-K
- 17 Mar 2025Filed a report · SEC 6-K
- 17 Mar 2025Filed a report · SEC 6-K
- 17 Mar 2025Filed a report · SEC 6-K
- 12 Mar 2025Filed a report · SEC 6-K
- 7 Mar 2025Filed a report · SEC 6-K
- 7 Mar 2025Filed a report · SEC 6-K
- 7 Mar 2025Filed a report · SEC 6-K
- 7 Mar 2025Filed a report · SEC 6-K
- 6 Mar 2025Filed a report · SEC 6-K
- 5 Mar 2025Filed a report · SEC 6-K
- 3 Mar 2025Filed a report · SEC 6-K
- 3 Mar 2025Filed a report · SEC 6-K
- 28 Feb 2025Filed a report · SEC 6-K
- 26 Feb 2025Filed a report · SEC 6-K
- 19 Feb 2025Filed a report · SEC 6-K
- 18 Feb 2025Filed a report · SEC 6-K
- 18 Feb 2025Filed a report · SEC 6-K
- 18 Feb 2025Filed a report · SEC 6-K
- 18 Feb 2025Filed a report · SEC 6-K
- 6 Feb 2025Filed a report · SEC 6-K
- 3 Feb 2025Filed a report · SEC 6-K
- 3 Feb 2025Filed a report · SEC 6-K
- 28 Jan 2025Filed a report · SEC 6-K
- 21 Jan 2025Filed a report · SEC 6-K
- 17 Jan 2025Filed a report · SEC 6-K
- 2 Jan 2025Filed a report · SEC 6-K
- 26 Dec 2024Filed a report · SEC 6-K
- 23 Dec 2024Filed a report · SEC 6-K
- 16 Dec 2024Filed a report · SEC 6-K
- 5 Dec 2024Filed a report · SEC 6-K
- 4 Dec 2024Filed a report · SEC 6-K
- 2 Dec 2024Filed a report · SEC 6-K
- 2 Dec 2024Filed a report · SEC 6-K
- 25 Nov 2024Filed a report · SEC 6-K
- 20 Nov 2024Filed a report · SEC 6-K
- 18 Nov 2024Filed a report · SEC 6-K
- 15 Nov 2024Filed a report · SEC 6-K
- 15 Nov 2024Filed a report · SEC 6-K
- 13 Nov 2024Filed a report · SEC 6-K
- 12 Nov 2024Filed a report · SEC 6-K
- 12 Nov 2024Filed a report · SEC 6-K
- 12 Nov 2024Filed a report · SEC 6-K
- 12 Nov 2024Filed a report · SEC 6-K
- 8 Nov 2024Filed a report · SEC 6-K
- 1 Nov 2024Filed a report · SEC 6-K
- 30 Oct 2024Filed a report · SEC 6-K
- 21 Oct 2024Filed a report · SEC 6-K
- 7 Oct 2024Filed a report · SEC 6-K
- 1 Oct 2024Filed a report · SEC 6-K
- 26 Sep 2024Filed a report · SEC 6-K
- 23 Sep 2024Filed a report · SEC 6-K
- 23 Sep 2024Filed a report · SEC 6-K
- 20 Sep 2024Filed a report · SEC 6-K
- 18 Sep 2024Filed a report · SEC 6-K
- 13 Sep 2024Filed a report · SEC 6-K
- 3 Sep 2024Filed a report · SEC 6-K
- 16 Aug 2024Filed a report · SEC 6-K
- 1 Aug 2024Filed a report · SEC 6-K
- 30 Jul 2024Filed a report · SEC 6-K
- 29 Jul 2024Filed a report · SEC 6-K
- 26 Jul 2024Filed a report · SEC 6-K
- 25 Jul 2024Filed a report · SEC 6-K
- 15 Jul 2024Filed a report · SEC 6-K
- 1 Jul 2024Filed a report · SEC 6-K
- 1 Jul 2024Filed a report · SEC 6-K
- 25 Jun 2024Filed a report · SEC 6-K
- 25 Jun 2024Filed a report · SEC 6-K
- 18 Jun 2024Filed a report · SEC 6-K
- 17 Jun 2024Filed a report · SEC 6-K
- 12 Jun 2024Filed a report · SEC 6-K
- 4 Jun 2024Filed a report · SEC 6-K
- 3 Jun 2024Filed a report · SEC 6-K
- 3 Jun 2024Filed a report · SEC 6-K
- 3 Jun 2024Filed a report · SEC 6-K
- 28 May 2024Filed a report · SEC 6-K
- 21 May 2024Filed a report · SEC 6-K
- 20 May 2024Filed a report · SEC 6-K
- 16 May 2024Filed a report · SEC 6-K
- 15 May 2024Filed a report · SEC 6-K
- 7 May 2024Filed a report · SEC 6-K
- 2 May 2024Filed a report · SEC 6-K
- 1 May 2024Filed a report · SEC 6-K
- 29 Apr 2024Filed a report · SEC 6-K
- 29 Apr 2024Filed a report · SEC 6-K
- 25 Apr 2024Filed a report · SEC 6-K
- 11 Apr 2024Filed a report · SEC 6-K
- 11 Apr 2024Filed a report · SEC 6-K
- 8 Apr 2024Filed a report · SEC 6-K
- 5 Apr 2024Filed a report · SEC 6-K
- 2 Apr 2024Filed a report · SEC 6-K
- 2 Apr 2024Filed a report · SEC 6-K
- 2 Apr 2024Filed a report · SEC 6-K
- 25 Mar 2024Filed a report · SEC 6-K
- 19 Mar 2024Filed a report · SEC 6-K
- 14 Mar 2024Filed a report · SEC 6-K
- 12 Mar 2024Filed a report · SEC 6-K
- 7 Mar 2024Filed a report · SEC 6-K
- 7 Mar 2024Filed a report · SEC 6-K
- 6 Mar 2024Filed a report · SEC 6-K
- 6 Mar 2024Filed a report · SEC 6-K
- 4 Mar 2024Filed a report · SEC 6-K
- 1 Mar 2024Filed a report · SEC 6-K
- 26 Feb 2024Filed a report · SEC 6-K
- 26 Feb 2024Filed a report · SEC 6-K
- 23 Feb 2024Offered new securities · 1 prospectus (424B2)
- 22 Feb 2024Filed a report · SEC 6-K
- 22 Feb 2024Filed a report · SEC 6-K
- 22 Feb 2024Filed a report · SEC 6-K
- 21 Feb 2024Offered new securities · 1 prospectus (424B2)
- 21 Feb 2024Filed a report · SEC 6-K
- 20 Feb 2024Filed a report · SEC 6-K
- 20 Feb 2024Filed a report · SEC 6-K
- 20 Feb 2024Filed a report · SEC 6-K
- 20 Feb 2024Filed a report · SEC 6-K
- 20 Feb 2024Filed a report · SEC 6-K
- 20 Feb 2024Filed a report · SEC 6-K
- 20 Feb 2024Filed a report · SEC 6-K
- 8 Feb 2024Filed a report · SEC 6-K
- 1 Feb 2024Filed a report · SEC 6-K
- 19 Jan 2024Filed a report · SEC 6-K
- 2 Jan 2024Filed a report · SEC 6-K
About
- No active trial
- 136 other drugs
- Registry names
- 3 names in ClinicalTrials.gov AstraZeneca
MedImmune LLC
Acerta Pharma BV - Sources
- ClinicalTrials.gov updated 16 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev